Development of sustained-release microspheres for the delivery of SAR 1118, an LFA-1 antagonist intended for the treatment of vascular complications of the eye

Journal of Ocular Pharmacology and Therapeutics

Volumn 29, Issue 2, 2013, Pages 236-248

  Yandrapu, Sarath ^a   Kompella, Uday B ^a,b,c  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c University of Colorado at Denver   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIFITEGRAST; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MICROSPHERE; POLYGLACTIN; POLYMER;

ARTICLE; CONTROLLED STUDY; DEGRADATION; ENCAPSULATION; EXPERIMENTAL DESIGN; EYE DISEASE; EYE VASCULAR DISEASE; FACTORIAL DESIGN; IN VITRO STUDY; PARTICLE SIZE; SUSTAINED RELEASE FORMULATION; VISCOSITY;

DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; EYE DISEASES; LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1; MICROSPHERES; PHENYLALANINE; SULFONES; VASCULAR DISEASES;

EID: 84875038704     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2012.0210     Document Type: Article

References (27)

1. Del Amo, E.M., & Urtti, A. Current and future ophthalmic drug delivery systems. A shift to the posterior segment. Drug Discov. Today. 13:135-143, 2008.
2. Herrero-Vanrell, R., & Refojo, M.F. Biodegradable microspheres for vitreoretinal drug delivery. Adv. Drug Deliv. Rev. 52:5-16, 2001.
3. Ayalasomayajula, S.P., & Kompella, U.B. Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model. Eur. J. Pharmacol. 511:191-198, 2005.
4. Kompella, U.B., Kadam, R.S., & Lee, V.H. Recent advances in ophthalmic drug delivery. Ther. Deliv. 1:435-456, 2011.
5. Shive, M.S., & Anderson, J.M. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv. Drug Deliv. Rev. 28:5-24, 1997.
6. Short, B.G. Safety evaluation of ocular drug delivery formulations: techniques and practical considerations. Toxicol. Pathol. 36:49-62, 2008.
7. Kimura, H., & Ogura, Y. Biodegradable polymers for ocular drug delivery. Ophthalmologica. 215:143-155, 2001.
8. Semba, C.P., Torkildsen, G.L., Lonsdale, J.D., McLaurin, E.B., Geffin, J.A., Mundorf, T.K., Kennedy, K.S., & Ousler, G.W. A phase 2 randomized, double-masked, placebocontrolled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye. Am. J. Ophthalmol. 153:1050-1060 e1051, 2012.
9. Gadek, T.R., Burdick, D.J., McDowell, R.S., Stanley, M.S., Marsters Jr., J.C., Paris, K.J., Oare, D.A., Reynolds, M.E., Ladner, C., Zioncheck, K.A., Lee, W.P., Gribling, P., Dennis, M.S., Skelton, N.J., Tumas, D.B., Clark, K.R., Keating, S.M., Beresini, M.H., Tilley, J.W., Presta, L.G., & Bodary, S.C. Generation of an LFA-1 antagonist by the transfer of the ICAM-1 immunoregulatory epitope to a small molecule. Science. 295:1086-1089, 2002.
10. Rao, V.R., Prescott, E., Shelke, N.B., Trivedi, R., Thomas, P., Struble, C., Gadek, T., O'Neill, C.A., & Kompella, U.B. Delivery of SAR 1118 to the retina via ophthalmic drops and its effectiveness in a rat streptozotocin (STZ) model of diabetic retinopathy (DR). Invest. Ophthalmol. Vis. Sci. 51:5198-5204, 2010.
11. Singh, B., Kumar, R., & Ahuja, N. Optimizing drug delivery systems using systematic "design of experiments." Part I: fundamental aspects. Crit. Rev. Ther. Drug Carrier Syst. 22:27-105, 2005.
12. Singh, B., Dahiya, M., Saharan, V., & Ahuja, N. Optimizing drug delivery systems using systematic "design of experiments." Part II: retrospect and prospects. Crit. Rev. Ther. Drug Carrier Syst. 22:215-294, 2005.
13. Ferreira, S.L., Bruns, R.E., Ferreira, H.S., Matos, G.D., David, J.M., Brandao, G.C., da Silva, E.G., Portugal, L.A., dos Reis, P.S., Souza, A.S., & dos Santos, W.N. Box-Behnken design: an alternative for the optimization of analytical methods. Anal. Chim. Acta. 597:179-186, 2007.
14. Araujo, P.W., & Brereton, R.G. Experimental design I. Screening. Trends Anal. Chem. 15:26-31, 1996.
15. Zidan, A.S., Sammour, O.A., Hammad, M.A., Megrab, N.A., Habib, M.J., & Khan, M.A. Quality by design: understanding the formulation variables of a cyclosporine A self-nanoemulsified drug delivery systems by Box-Behnken design and desirability function. Int. J. Pharm. 332:55-63, 2007.
16. Box, G.E.P., & Behnken, D.W. Some new three-level designs for the study of quantitative variables. Technometrics. 2:455-475, 1960.
17. Shelke, N.B., Kadam, R., Tyagi, P., Rao, V.R., & Kompella, U.B. Intravitreal poly(L-lactide) microparticles sustain retinal and choroidal delivery of TG-0054, a hydrophilic drug intended for neovascular diseases. Drug Deliv. Transl. Res. 1:76-90, 2011.
18. Guo, C., Stine, K.J., Kauffman, J.F., & Doub, W.H. Assessment of the influence factors on in vitro testing of nasal sprays using Box-Behnken experimental design. Eur. J. Pharm. Sci. 35:417-426, 2008.
19. Singare, D.S., Marella, S., Gowthamrajan, K., Kulkarni, G.T., Vooturi, R., & Rao, P.S. Optimization of formulation and process variable of nanosuspension: an industrial perspective. Int. J. Pharm. 402:213-220, 2010.
20. Ozurdex (dexamethasone intravitreal) implant.http://www .fda.gov/Safety/MedWatch/SafetyInformation/ucm295117 .htm
21. Wischke, C., & Schwendeman, S.P. Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles. Int. J. Pharm. 364:298-327, 2008.
22. Yang, Y.Y., Chung, T.S., & Ng, N.P. Morphology, drug distribution, and in vitro release profiles of biodegradable polymeric microspheres containing protein fabricated by double-emulsion solvent extraction/evaporation method. Biomaterials. 22:231-241, 2001.
23. Malaekeh-Nikouei, B., Sajadi Tabassi, S.A., & Jaafari, M.R. The effect of different grades of PLGA on characteristics of microspheres encapsulated with cyclosporine A. Curr. Drug Deliv. 3:343-349, 2006.
24. Bodmeier, R., & McGinity, J.W. Polylactic acid microspheres containing quinidine base and quinidine sulphate prepared by the solvent evaporation method. III. Morphology of the microspheres during dissolution studies. J. Microencapsul. 5:325-330, 1988.
25. Jain, V., Jain, D., & Singh, R. Factors effecting the morphology of eudragit S-100 based microsponges bearing dicyclomine for colonic delivery. J. Pharm. Sci. 100:1545-1552, 2010.
26. Mittal, G., Sahana, D.K., Bhardwaj, V., & Ravi Kumar, M.N. Estradiol loaded PLGA nanoparticles for oral administration: effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo. J. Control Release. 119:77-85, 2007.
27. Shekunov, B.Y., Chattopadhyay, P., Tong, H.H., and Chow, A.H. Particle size analysis in pharmaceutics: principles, methods and applications. Pharm. Res. 24:203-227, 2007.